BMEA
$1.22
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.
Intraday
Recent News
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027
Biomea Fusion (NASDAQ:BMEA) outlined its focus on diabetes and obesity at the Citizens Life Sciences Conference, highlighting two internally developed programs and a series of clinical milestones expected over the coming quarters. President Ramses Erdtmann said the company is funded through the firs
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference appearance featuring CEO Mick Hitchcock and COO Ramses Erdtmann. The company discussed two lead programs: icovamenib, an oral small-molecule menin inhibitor being developed for diabe
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38%
Key Insights Biomea Fusion's significant retail investors ownership suggests that the key decisions are influenced by...
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target
Biomea Fusion Inc. (NASDAQ:BMEA) is one of the overlooked growth stocks to buy. On January 14, Rodman & Renshaw initiated coverage of Biomea Fusion with a Buy rating and $8 price target. In Q3 2025, Biomea announced that the company was shifting its strategy to focus on its two primary assets: icovamenib, a menin inhibitor […]
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones
Biomea Fusion (NASDAQ:BMEA) highlighted two clinical-stage programs focused on diabetes and obesity during a presentation at the 44th Annual JPMorgan Healthcare Conference, with CEO Mick Hitchcock outlining recent data, planned studies, and key milestones for 2026 and beyond. Company focus and pipe